Sperm Proteome Maturation in the Mouse Epididymis

Sheri Skerget, Matthew Rosenow, Konstantinos Pétritis, +1

PLoS ONE

SpermatogenesisFertilityGeneticsSemen AnalysisReproductive Biology +15

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

Kristine A. Frerichs, Christie P.M. Verkleij, María‐Victoria Mateos, +21

Blood Advances

Humoral ResponseImmunologyImmunoeditingPathologyImmunotherapy +14

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Sheri Skerget, Daniel Peñaherrera, Ajai Chari, +11

Nature Genetics

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study

Ajai Chari, Cyrille Touzeau, Carolina Schinke, +31

The Lancet Haematology

Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPathology +5

The Rhesus Macaque (Macaca mulatta) Sperm Proteome

Sheri Skerget, Matthew Rosenow, Ashoka D. Polpitiya, +3

Molecular & Cellular Proteomics

BiologyInfertilityDevelopmental BiologyFertilityMedicine +11

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

Holly Lee, Michael Durante, Sheri Skerget, +15

Blood

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Diana Cortés‐Selva, Tineke Casneuf, Deeksha Vishwamitra, +24

Blood

Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study

Andrzej Jakubowiak, Sébastien Anguille, Lionel Karlin, +13

Blood

T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma

Christie P.M. Verkleij, Chloe O’Neill, Marloes E.C. Broekmans, +11

Clinical Cancer Research

Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma

Georgina S.F. Anderson, José Ballester‐Beltrán, George Giotopoulos, +25

Blood

Effective Immunotherapy TargetCancer ImmunosurveillanceImmunologyCell SurfaceCancer Genomics +12